Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 101–200 of 1,004
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
McDougall, S. R., Anderson, A. R. A., & Chaplain, M. A. J. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.12.022 · Cited by 383
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela-Arispe, M. L., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 356
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
“Angiogenesis is an es ential pro ess i can er and in diabe ic retinopathy, in which the cells are characterized by abnormal vasculature structure and fun tions such as tortuous, dilat d, saccul vessels and high permeability [7,8,10,11].”
BackgroundWachsberger, P. R., Burd, R., & Dicker, A. P. (2003) · PubMed · Cited by 394
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 350
Endothelial Cell Metabolism in Health and Disease
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., & Carmeliet, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 335
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Self-citationAdvancing the field of drug delivery
Moses, M. A., Brem, H., & Langer, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00276-9 · Cited by 343
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Is diabetic retinopathy an inflammatory disease?
Adamis, A. P. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.4.363 · Cited by 341
Layer-by-Layer Nanoparticles with a pH-Sheddable Layer for in Vivo Targeting of Tumor Hypoxia
Poon, Z., Chang, D., Zhao, X., & Hammond, P. T. (2011) · ACS Nano · doi:10.1021/nn200876f · Cited by 343
“Additionally, as hypoxia and subsequent acidosis are orchestrating forces for tumor cells to acquire resistance to chemotherapy and radiation,(39,40) this form of targeting also provides opportunities for therapies that sensitize hypoxic tumor cells to treatment.(41,42)”
BackgroundMarkers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
“In the past years, the normalization theory proposed by Jain (2001) has gained widespread acceptance for explaining additional antitumor effects of inhibitors of VEGF signaling, when combined with cytotoxic drugs.”
BackgroundIntegrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334
Clinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement
Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 327
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Vempati, P., Popel, A. S., & Mac Gabhann, F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.11.002 · Cited by 313
Hyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy
Gong, H., Chao, Y., Xiang, J., Han, X., Song, G., Feng, L., Liu, J., Yang, G., Chen, Q., & Liu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00068 · Cited by 322
The impact of hypoxia and its modification of the outcome of radiotherapy
Horsman, M. R., & Overgaard, J. (2016) · Journal of Radiation Research · doi:10.1093/jrr/rrw007 · Cited by 311
Spaide, R. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.012 · Cited by 313
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Current approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Zhu, A. X., Meyerhardt, J. A., Blaszkowsky, L. S., Kambadakone, A. R., Muzikansky, A., Zheng, H., Clark, J. W., Abrams, T. A., Chan, J. A., Enzinger, P. C., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70333-x · Cited by 303
Vessel Tortuosity and Brain Tumor Malignancy
Bullitt, E., Zeng, D., Gerig, G., Aylward, S., Joshi, S., Smith, J. K., Lin, W., & Ewend, M. G. (2005) · Academic Radiology · doi:10.1016/j.acra.2005.05.027 · Cited by 285
Sorensen, A. G., Emblem, K. E., Polaskova, P., Jennings, D., Kim, H., Ancukiewicz, M., Wang, M., Wen, P. Y., Ivy, P., Batchelor, T. T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2464 · Cited by 295
Self-citationCombining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
Self-citationTeo, R. D., Hwang, J. Y., Termini, J., Gross, Z., & Gray, H. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00400 · Cited by 289
New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles
Zaimy, M. A., Saffarzadeh, N., Mohammadi, A., Pourghadamyari, H., Izadi, P., Sarli, A., Moghaddam, L. K., Paschepari, S. R., Azizi, H., Torkamandi, S., et al. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.16 · Cited by 289
Granados-Romero, J. J., Valderrama-Treviño, A. I., Contreras-Flores, E. H., Barrera-Mera, B., Herrera Enríquez, M., Uriarte-Ruíz, K., Ceballos-Villalba, J. C., Estrada-Mata, A. G., Alvarado Rodríguez, C., & Arauz-Peña, G. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20174914 · Cited by 279
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 272
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T. M., Corti, A., & Ponzoni, M. (2003) · PubMed · Cited by 296
Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor
JAIN, R. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70063-8 · Cited by 256
Self-citationPerspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole
Lee, S. T., & Scott, A. M. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.07.001 · Cited by 283
Dings, R. P. M., Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., & Griffin, R. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2441 · Cited by 286
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
Weigelt, B., & Bissell, M. J. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.013 · Cited by 273
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Self-citationNanotechnology for angiogenesis: opportunities and challenges
Kargozar, S., Baino, F., Hamzehlou, S., Hamblin, M. R., & Mozafari, M. (2020) · Chemical Society Reviews · doi:10.1039/c8cs01021h · Cited by 262
Contribution of Tumor Endothelial Cells in Cancer Progression
Hida, K., Maishi, N., Annan, D., & Hida, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051272 · Cited by 259
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
MATHEMATICAL MODELING OF TUMOR-INDUCED ANGIOGENESIS
Chaplain, M. A. J., McDougall, S. R., & Anderson, A. R. A. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095807 · Cited by 255
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Zhu, A. X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-790 · Cited by 260
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Lucio-Eterovic, A. K., Piao, Y., & de Groot, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0575 · Cited by 243
Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis
Doyle, B., & Caplice, N. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.089 · Cited by 246
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
Herbst, R. S., Onn, A., & Sandler, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.853 · Cited by 246
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Madu, C. O., Wang, S., Madu, C. O., & Lu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.44313 · Cited by 249
Horsman, M. R., & Siemann, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2848 · Cited by 246
“This stabilization period has been termed the ‘‘normalization window’’ (68).”
Antiangiogenic therapy and tumor progression
Blagosklonny, M. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00336-2 · Cited by 235
Los, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
Three-dimensional multispecies nonlinear tumor growth—II: Tumor invasion and angiogenesis
Frieboes, H. B., Jin, F., Chuang, Y.-L., Wise, S. M., Lowengrub, J. S., & Cristini, V. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.02.036 · Cited by 232
“An important element is the tumor microvasculature, which tends to be highly disorganized (Hashizume et al., 2000; Jain, 2001a), resulting in considerable heterogeneity in delivery of cell substrates (e.g., oxygen, nutrients, and growth factors) and metabolite removal (Jain, 1988, 1990).”
BackgroundAntiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways
Sørensen, B. S., & Horsman, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00562 · Cited by 229
“This stabilization process was termed “normalization” (86) and the more stable, organized vasculature that resulted would likely lead to a better delivery of oxygen and nutrients to the tumor, thus reducing the degree of tumor hypoxia.”
BackgroundMechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
Scappaticci, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.033 · Cited by 225
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
Recent advances in systemic therapy for hepatocellular carcinoma
Zhang, H., Zhang, W., Jiang, L., & Chen, Y. (2022) · Biomarker Research · doi:10.1186/s40364-021-00350-4 · Cited by 214
Berger, M., Bergers, G., Arnold, B., Hämmerling, G. J., & Ganss, R. (2005) · Blood · doi:10.1182/blood-2004-06-2315 · Cited by 222
van der Schaft, D. W. J., Seftor, R. E. B., Seftor, E. A., Hess, A. R., Gruman, L. M., Kirschmann, D. A., Yokoyama, Y., Griffioen, A. W., & Hendrix, M. J. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh267 · Cited by 219
Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia
Elming, P., Sørensen, B., Oei, A., Franken, N., Crezee, J., Overgaard, J., & Horsman, M. (2019) · Cancers · doi:10.3390/cancers11010060 · Cited by 205
Li, W., Li, F., Zhang, X., Lin, H.-K., & Xu, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 198
Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Gröne, H.-J., Hallahan, D. E., Reisfeld, R. A., Debus, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1223 · Cited by 205
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Gerstner, E. R., Duda, D. G., di Tomaso, E., Ryg, P. A., Loeffler, J. S., Sorensen, A. G., Ivy, P., Jain, R. K., & Batchelor, T. T. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.14 · Cited by 208
Self-citationDíaz-Rubio, E., Gómez-España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., Martínez de Prado, P., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210
Brudno, Y., Ennett-Shepard, A. B., Chen, R. R., Aizenberg, M., & Mooney, D. J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.007 · Cited by 204
Tugues, S., Koch, S., Gualandi, L., Li, X., & Claesson-Welsh, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 205
Datta, M., Via, L. E., Kamoun, W. S., Liu, C., Chen, W., Seano, G., Weiner, D. M., Schimel, D., England, K., Martin, J. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424563112 · Cited by 207
“In this study we show, for the first time to our knowledge, in a rabbit model of TB that treatment with bevacizumab normalizes granuloma vasculature, reduces hypoxia, and enhances small molecule delivery during a “window of normalization,” a transient effect observed in tumors (15, 20).”
BackgroundSelf-citationRecent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
Huo, D., Jiang, X., & Hu, Y. (2020) · Advanced Materials · doi:10.1002/adma.201904337 · Cited by 205
Kiessling, F., Greschus, S., Lichy, M. P., Bock, M., Fink, C., Vosseler, S., Moll, J., Mueller, M. M., Fusenig, N. E., Traupe, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1101 · Cited by 205
Maharaj, A. S. R., & D'Amore, P. A. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.03.004 · Cited by 195
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, B. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00013-3 · Cited by 193
Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks
Pries, A. R., Cornelissen, A. J. M., Sloot, A. A., Hinkeldey, M., Dreher, M. R., Höpfner, M., Dewhirst, M. W., & Secomb, T. W. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000394 · Cited by 192
Ghosh, K., Thodeti, C. K., Dudley, A. C., Mammoto, A., Klagsbrun, M., & Ingber, D. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800835105 · Cited by 188
Humphrey, J. S., Price, K., Gupta, E., Baxter, A., Bird, J., Sonnichsen, D., & Naglich, J. (2003) · Chemoradiation in Cancer Therapy · doi:10.1007/978-1-59259-325-5_21 · Cited by 193
Extravasation of polymeric nanomedicines across tumor vasculature
Danquah, M. K., Zhang, X. A., & Mahato, R. I. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.005 · Cited by 188
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
You, W.-K., & McDonald, D. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.12.833 · Cited by 190
From Nanotechnology to Nanomedicine: Applications to Cancer Research
Seigneuric, R., Markey, L., S.A. Nuyten, D., Dubernet, C., T.A. Evelo, C., Finot, E., & Garrido, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410792630634 · Cited by 182
The challenge of targeting metastasis
Fidler, I. J., & Kripke, M. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9586-9 · Cited by 185
Nonlinear simulation of the effect of microenvironment on tumor growth
Macklin, P., & Lowengrub, J. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.12.004 · Cited by 191
Scaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182
Self-citationChoi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
“These unexpected outcomes were termed the “ AAT paradox “ 21 , and the concept of “ vascular normalization ” was proposed by Rakesh K. Jain in 2001 to explain this phenomenon 38 .”
BackgroundIntricacies of Bevacizumab-Induced Toxicities and Their Management
Gressett, S. M., & Shah, S. R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l426 · Cited by 187
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan, R., Ebel, W., Routhier, E., Patel, R. K., Kline, J. B., Zhang, J., Chao, Q., Jacob, S. M., Turchin, H. A., Gibbs, L. S., et al. (2007) · PubMed · Cited by 186
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Giavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., Ronca, R., Tosatti, M. P. M., & Presta, M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64325-8 · Cited by 185
Huber, P. E., Bischof, M., Jenne, J., Heiland, S., Peschke, P., Saffrich, R., Gröne, H.-J., Debus, J., Lipson, K. E., & Abdollahi, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1668 · Cited by 185
Pathological angiogenesis and inflammation in tissues
Jeong, J.-H., Ojha, U., & Lee, Y. M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01287-2 · Cited by 174
Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 176
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.